MIDDLETOWN, Pa.—MacuLogix, Inc.
, which equips eyecare professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), has launched its AMD Academy
. The AMD Academy is an online learning community for current AdaptDx users, delivering video-based product training and a user forum to facilitate discussion of best practices and answers to user questions.
“MacuLogix provides extensive, in-person training to each new customer through our AMD Excellence Program; and our new AMD Academy complements this program by creating an online community for our users,” said WilliamMcPhee,president and CEO of MacuLogix. “We are excited to provide this platform for our customers, where they can share best practices and interact with our AMD Experts.”
The AMD Academy launches with a comprehensive learning plan for the AdaptDx automated dark adaptometer, featuring 21 short, video-based learning modules. New users can quickly learn how to operate the AdaptDx by viewing videos on how to prepare and run the test, how to manage patient data, and more.
After completing the courses, learners will earn an AdaptDx Online Training Certificate. Experienced AdaptDx users can also access the learning modules at any time to revisit certain topics and glean or share helpful tips on the discussion forum.
“The AMD Academy is an accessible, online extension of the outstanding training our Practice Management Consultants (PMCs) deliver to all new AdaptDx customers. Our PMC team is excited for the opportunity to expand their relationship with our customers by actively participating in the community forum,” said Robin Mattson, vice president of customer experience for MacuLogix. “My hope is that we continue to learn from our users and share that knowledge across our customer base.”
The AMD Academy is available at no cost to current customers of MacuLogix. Additional learning modules, including best practices, practice workflow and general education on age-related macular degeneration, will be added in the future.
MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients.